Kornimate/medical-research-clean huggingface dataset:
pillbot™ - remotely controlled capsule endoscopy

Conditions: Gastric Disease

Summary: the pillbot system is an endoscopic capsule imaging system intended for visualization of the stomach. in contrast to currently used passive capsule endoscopy systems, and fda cleared active magnetic system, the pillbot system uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * ability to provide written, informed consent to undergo both capsule endoscopy (un-sedated) and conventional ogd * willing and able to complete study follow-up requirements * patient has appropriate indications for upper endoscopy including symptoms of, but not limited to upper abdominal pain, acid reflux, heartburn, iron deficiency anemia, weight loss, bloating, belching, nausea, vomiting and atypical chest pain exclusion criteria: all patients who meet any of the following criteria should not be enrolled into the study: * coagulopathy with inr \> 1.5, thrombocytopenia with platelet counts \< 50,000 * active bleeding * need for therapeutic procedures during endoscopy * lactation * dysphagia, or other swallowing disorders * known esophageal diverticulum or stricture * swallowing disorder * known luminal, gastrointestinal strictures * patient with crohn's disease or other potential obstructive conditions, unless there is a recent computed tomography enterography (cte) or magnetic resonance enterography (mre), mre or patency capsule performed to exclude an obstructive lesion that may retain the capsule * history of esophageal, gastric surgery or intestinal surgery * esophageal or gi motility disorder * known or suspected gastrointestinal obstruction, significant intestinal strictures, or fistulas based on the clinical picture or pre-procedure testing and profile. * current participation in another investigational drug or device treatment study * pregnant or wishes to become pregnant during the study follow-up period * patient with implanted medical device that would be potentially affected radiofrequency emissions (e.g., pacemakers, implanted cardiac defibrillators) * severe psychiatric, neurological, cardio-vascular, or renal disorders * history of allergy or intolerance to materials used to make the pillbot
real life effectiveness in asthma of symbicort single inhaler therapy

Conditions: Asthma

Summary: the purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.


Eligibility criteria:
inclusion criteria: * aged over 18 * confirmed diagnosis of mild to moderate asthma by doctor * currently receiving inhaled corticoid-steroid medicine for treatment of asthma and requiring a review of current asthma treatment exclusion criteria: * women who are pregnant, breast-feeding, or planning pregnancy * patients with a history of chronic obstructive pulmonary disease * patients using any beta blocker therapy * patients receiving steroid tablets or steroid injections

Keywords: respiratory tract diseases bronchial diseases anti-asthmatic agents anti-asthmatic drugs bronchodilators
adjuvanted inactivated vaccine versus inactivated influenza vaccine in hutterite children

Conditions: Influenza

Summary: this study is a randomized controlled trial (rct) comparing adjuvanted influenza vaccine (av) to unadjuvanted inactivated influenza vaccine (iiv). children in hutterite colonies in alberta and saskatchewan will receive av or iiv. the goal of this study is to determine whether the av vaccine, can provide increased community-wide protection.


Eligibility criteria:
group a: receive intervention inclusion criteria: -healthy children aged 6 months to 72 months exclusion criteria: * anaphylactic reaction to a previous dose of influenza vaccine or to any of its components * known immunoglobulin e (ige)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock * guillain- barré syndrome within eight weeks of a previous influenza vaccine * use of aspirin or salicylate- containing products within 30 days before enrollment group b: inclusion criteria: * household and extended family members of children in group a * extended family is defined as the household members of the grandparents of the children in group a exclusion criteria: * there are no exclusion criteria for this category of participants group c: inclusion criteria: * other hutterite community members that are not in group a exclusion criteria: * there are no exclusion criteria for this category of participants
evaluation of monitoring technologies in the peri-operative care of cardiac surgical patients

Conditions: C.Surgical Procedure; Cardiac; Right-Sided Heart Failure; Acute Kidney Injury; Respiratory Insufficiency; Postoperative Complications

Summary: the purpose of this prospective observational cohort study is to evaluate multimodal monitoring technologies in the perioperative care of cardiac surgical patients. right ventricular pressure tracings, near infrared spectroscopy (nirs) and transthoracic ultrasonography will be studied for their ability to detect and predict complications such as right ventricular failure, renal failure and respiratory failure.

the study has 4 main objectives: 1. to determine if right ventricular pressure tracings correlate with other indices of right ventricular failure and with positive fluid balance, renal failure and increased length of stay in the intensive care unit. 2. to determine the prevalence of portal vein pulsatility in the perioperative period and its association with right ventricular failure and positive fluid balance. 3. to determine if near infrared spectroscopy (nirs) values correlate with mixed venous oxygen saturation (svo2) and with poorer post-operative prognosis. 4. to determine the incidence, risk factors and prognosis of respiratory complications of cardiac surgery using transthoracic ultrasonography.

Eligibility criteria:
inclusion criteria: * cardiac surgery performed at the montreal heart institute * 18 years old and older exclusion criteria: * urgent surgery * pre-operative intra-aortic balloon pump, left ventricular assist device or ecmo * heart transplant * cirrhosis

Keywords: near infrared spectroscopy ultrasonography hepatic vein doppler portal vein doppler lung ultrasound positive fluid balance mixed venous saturation
impact of family psychoeducation on psychosis

Conditions: Postpartum Psychosis

Summary: there is currently no clear involvement of families/caregivers in the care for postpartum mothers that develop postpartum psychosis. the lack of knowledge on causes of postpartum psychosis may influence the nature of perceived social support that mothers receive from caregivers. it is hoped that the provision of a culturally adapted version of family psychoeducation will bridge the knowledge gap and provide the much needed information. we therefore hypothesized that the involvement of a family member of a postpartum mother with a psychotic illness in a weekly session of family psychoeducation.

postpartum psychosis causes distress to the mother, baby, spouse and other primary caregivers. this is especially true for uganda where cultural beliefs for the causation of the illness place blame on supposedly the postpartum mother's promiscuity during pregnancy (cox, 1979). cultural perceptions on the causes of postpartum psychosis may affect the nature of social support the mothers perceive from their families when they develop the illness. other perceptions regarding postpartum psychosis in uganda lay blame on supernatural causes like witchcraft. family psychoeducation which sets out to inform families of the nature of the illness is called for so as to demystify the illness.

Eligibility criteria:
inclusion criteria: * postpartum mothers with a psychiatric illness in the current postpartum period. * must have been admitted to the mental health facility for the current episode. exclusion criteria: * mothers residing out of a radius of 50 km away from the health facility. * mothers that do not have caregivers. * mothers who are not fluent in the language in which the study will be conducted.

Keywords: postpartum psychosis perceived social support family psychoeducation
pharmacokinetics and safety of alks 5461 in subjects with renal impairment and normal renal function

Conditions: Renal Impairment

Summary: this study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of alks 5461.


Eligibility criteria:
inclusion criteria: for all subjects: * has a body mass index (bmi) of 18.0-40.0 kg/m\^2 and a total body weight \>50kg * agrees to use an approved method of contraception for the duration of the study * additional criteria may apply for subjects with renal impairment: * has severe or end stage renal disease, and does not require dialysis * has stable renal function for at least 60 days preceding screening * additional criteria may apply exclusion criteria: for all subjects: * has any past history or current finding of a clinically significant observed abnormality, psychiatric or medical condition other than renal impairment * has a history of gastrointestinal surgery affecting drug absorption or biliary elimination, excluding appendectomy or cholecystectomy * is pregnant, planning to become pregnant, or lactating * has a history of clinically significant allergy or a hypersensitivity to opioids * additional criteria my apply for subjects with renal impairment: * has evidence of compromised respiratory function, seizure disorder, or myasthenia gravis * has received a kidney transplant * additional criteria may apply

Keywords: alks 5461 alkermes samidorphan renal impairment pharmacokinetics buprenorphine
extension study of carvedilol rct study

Conditions: Liver Cirrhosis; Portal Hypertension

Summary: patients who have completed 2-years treatment in rct study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated hbv cirrhotic patients.

carvedilol has been shown to be more potent in decreasing portal hypertension than propranolol. but the efficacy of carvedilol to prevent esophageal varices progression in nucleoside analogue (nucs) treatment hbv related cirrhotic patients was unclear. previous rct study aimed to explore the effects of carvedilol for the prevention of the esophageal varices progression on hbv cirrhotic patients with anti-viral therapy has been conducted (nct03736265). patients who have completed 2-years treatment in rct study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated hbv cirrhotic patients. patients were allocated according to the outcome of edgs at 2-year during rct study. patients will be assessed at baseline and every six months for blood cell count, liver function test, hbvdna, afp, prothrombin time, liver ultrasonography, and fibroscan. a third egds will be performed at 4-year.

Eligibility criteria:
inclusion criteria: * subjects who completed the 2-year rct study of carvedilol in hbv cirrhotic patients with anti-viral therapy; * subjects who are willing to participate the extension study. exclusion criteria: * subjects who refused to receive 2-year egd examination during the previous rct study; * subjects who could not compliance with the protocol judged by investigators; * subjects who are not suitable for the study judged by investigators.

Keywords: portal hypertension esophageal varices carvedilol
trial of the effects of remote preconditioning on the tissue metabolism during exercise and ischemia

Conditions: Ischemia

Summary: previously, the preconditioning signaling pathways have been studied on molecular level or in animal model. by using mr spectroscopy and imaging in a dynamic human model of preconditioning, we will have a better understanding how mitochondrial and endothelial function are affected by preconditioning in-vivo.

ischemic preconditioning is a mechanism that protects tissue against ischemia-reperfusion injury. the protective effect of preconditioning is induced by short periods (1-5 minutes) of non-lethal ischemia to the target tissue, which becomes resistant to a prolonged, otherwise lethal, period of ischemia. despite its proven potency in experimental models, ischemic preconditioning has not reached widespread clinical application because of the difficulties in applying the stimulus to the target organ (eg heart, brain), and even brief ischemia to the target organ can cause dysfunction. remote ischemic preconditioning (ripc) is a more clinically relevant stimulus. it has been shown that preconditioning of one coronary territory induces ischemia protection in other parts of the heart. subsequently, other studies have shown, in rodent models, that preconditioning of one organ (eg kidney) could induce protection in other organs (eg heart). we recently have confirmed, in a series of animal and human preclinical studies, that this concept can be widened; ultimately showing that four 5-minute episodes of ischemia to the skeletal limb muscles (induced by inflating a standard blood pressure cuff to a level higher than the blood pressure) protects the heart and lungs against ischemia-reperfusion injury in children undergoing cardiac surgery using cardiopulmonary bypass. the current research is designed to investigate with mri spectroscopy techonology, the potential physiological mechanisms involved in the protective effects of preconditioning, and the effects of ischemia and exercise.

Eligibility criteria:
inclusion criteria: * healthy male and female volunteers * post-pubescent non-athletes between the ages of \>16 and \<40 years of age. exclusion criteria: * older than 40 year old. * younger than 16 year old. * major medical condition * illness, surgery or medical intervention in the last 48 hours. * diabetes mellitus * caffeine intake in the last 48 hours * athlete (more than 5 training sessions per week)

Keywords: exercise ischemia mri mri spectroscopy ischemia preconditioning
a clinical study in male pediatric patients with cerebral x-linked adrenoleukodystrophy (cald) to assess the effects of min-102 treatment on disease progression prior to human stem cell transplant (hsct)

Conditions: Cerebral Adrenoleukodystrophy

Summary: an open-label, multicenter study in male pediatric patients with cerebral x-linked adrenoleukodystrophy (cald) to assess the effects of min-102 treatment on disease progression prior to human stem cell transplant (hsct)


Eligibility criteria:
inclusion criteria: * males aged ≥2 and ≤12 years with a diagnosis of x-linked ald * white matter involvement as determined by cerebral mri lesions without gd enhancement at baseline (population 1), or with gd enhancement at baseline (population 2). * major functional disabilities (mfd) score of 0. * baseline loes score \>0 and ≤10 * gadolinium intensity score \>2 exclusion criteria: * previous hsct * too far progressed inflammatory brain lesions
effect of superficial neuromuscular stimulation in post-stroke dysphagic patients.

Conditions: Dysphagia; Stroke

Summary: swallowing disorder in stroke patients is a significant cause of morbidity and mortality as it can cause aspiration pneumonia. electrical stimulation has proven to be effective in post-stroke dysphagic patients.10 patients who have symptoms of post-stroke dysphagia, meet the inclusion criteria and volunteer to participate will be included in the study. included patients will be randomized into 2 groups. the exercise program will be applied to both groups as a home program for 4 weeks.

a randomized, prospective, controlled study will include 10 patients with post-stroke dysphagia. groups will be randomized into 2 groups. 1. st group; one electrode will be connected to the suprahyoid region and the other electrode will be connected between the thyroid and hyoid cartilages. superficial neuromuscular stimulation will be applied by the physiotherapist at 80 hz, 0-25 µa (microampere) current range for 20 minutes, for 5 days for the patient, for a total of 4 weeks. at the same time, each patient will be taught the exercises included in traditional swallowing treatment and will be advised to practice them for 30 minutes every day. 2. nd group; exercises such as progressively resistant oral-facial, lingual, laryngeal exercises, tongue strengthening exercises, effortful swallowing maneuver, thermal/tactile stimulation to oropharyngeal muscles, masako maneuver, mendelson maneuver, shaker maneuver, which are included in traditional swallowing treatment, will be taught and practiced for 30 minutes will be recommended for one month. patients' dysphagia scales, quality of life survey and ultrasonography measurements will be performed before and after treatment. tests to be applied * functional oral intake scale (foas) * swallowing function screening test (eat-10) * guss (gagging swallowing screening test) * modified mann swallowing ability assessment test (mmasa) * swal-qol (the impact of swallowing disorders on quality of life questionnaire), * measurements made by ultrasonography (measurement of tongue thickness, measurement of hyoid-larynx distance and measurements of other anatomical structures) clinic responsible for research: physical therapy and rehabilitation clinic of kayseri city hospital

Eligibility criteria:
inclusion criteria: * male and female patients over 40 years of age with post-stroke dysphagia * patients with functional oral intake scale (foas) 1-6 exclusion criteria: * patients younger than 40 years old * dementia, impaired consciousness or hypoesthetic /anesthetic patients * patients with low body mass * patients with pacemakers and severe heart disease * severe hypertension and hypotension * thrombosis or thrombophlebitis * pregnancy * epilepsy

Keywords: dysphagia post-stroke dysphagia rehabilitation ultrasonography
chp677: i-metaiodobenzylguanidine (i-mibg) therapy for refractory neuroblastoma: a phase ii study

Conditions: Neuroblastoma

Summary: 131i-metaiodobenzylguanidine (131i-mibg) is a norepinephrine analog that concentrates in adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma. this is a dual institution, phase ii study of 131i-mibg administered at the previously defined maximum practical dose of 18 mci/kg to children with relapsed or refractory neuroblastoma.


Eligibility criteria:
inclusion criteria: refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine vma with typical tumor cells in the bone marrow.

Keywords: relapsed and refractory neuroblastoma
effects of upper trapezius stretching with and without mid lower trapezius strengthening in trapezius myalgia

Conditions: Trapezius Myalgia

Summary: a randomized controlled trial will be conducted. non-probability convnience sampling will be used to collect the data. sample size of 42 subjects with age group between 18 to 40 years will be taken. data will be collected by using tools numeric pain rate scale (nprs) for pain, neck disability index (ndi) for disability and sf-36 for quality of life. an informed consent will be taken. a total of 20 subjects will be selected by following inclusion and exclusion criteria and will equally divided in to two groups by random number generator table. both groups will come thrice per week for a total of 4 weeks.

trapezius myalgiais the complaint of pain, stiffness, and tightness of the upper trapezius muscle. it is characterised by acute or persistent neck-shoulder pain. in today's society, due to the increased use of computers, where the neck and shoulders are maintained in static abnormal postures to look at the computer screens and become vulnerable to cause neck pain. the aim of the study is to determine effects of upper trapezius stretching with and without mid lower trapezius strengthening exercises on pain, disability and quality of life in females with work related trapezius myalgia. a randomized controlled trial will be conducted in physiotherapy outpatient department of bahria international hospital lahore. non-probability convnience sampling will be used to collect the data. sample size of 42 subjects with age group between 18 to 40 years will be taken. data will be collected by using tools numeric pain rate scale (nprs) for pain, neck disability index (ndi) for disability and sf-36 for quality of life. an informed consent will be taken. a total of 20 subjects will be selected by following inclusion and exclusion criteria and will equally divided in to two groups by random number generator table. both groups will come thrice per week for a total of 4 weeks. the data will be analysed using spss software version 25. after assessing normality of data by shapiro-wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

Eligibility criteria:
inclusion criteria: * • females between the age range of 18-40 years * examination-symptoms provoked by neck movement and palpation of trapezius musculature. * positive trapezius strength test exclusion criteria: * participants who present with dizziness and vertigo * infection or febrile state at the time of performing the test; * anxiety or extreme emotional tension; * pharmacological treatment (analgesics, muscle relaxants, anxiolytics, antidepressants) * disc lesions